SetPoint Medical

SetPoint Medical was founded in 2007 by Kevin Tracey, whose research at the Feinstein Institutes for Medical Research underpins its therapy, and is based in Valencia, California. It makes the SetPoint System, a small neurostimulator implanted on the vagus nerve in the neck that delivers electrical stimulation once a day to activate the body's anti-inflammatory pathways. The FDA approved the system on July 30, 2025 for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or cannot tolerate, biologic or targeted synthetic drugs, with support from the 242-patient RESET-RA trial. SetPoint is a commercial-stage company that sells the system to U.S. hospitals, where neurosurgeons implant it in patients referred by rheumatologists. In August 2025 it raised $140 million: a $25 million second tranche of its Series C plus a $115 million Series D led by Elevage Medical Technologies and Ally Bridge Group, with Abbott and Boston Scientific among the returning investors. It plans to test the platform in multiple sclerosis and Crohn's disease.